Enanta Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	2015 - 2019
Operating Revenue	66.59	67.64	79.2	86.16	97.07	122.47	Upgrade
Revenue	66.59	67.64	79.2	86.16	97.07	122.47	Upgrade
Revenue Growth (YoY)	-9.55%	-14.61%	-8.07%	-11.24%	-20.74%	-40.31%	Upgrade
Gross Profit	66.59	67.64	79.2	86.16	97.07	122.47	Upgrade
Selling, General & Admin	54.18	57.85	52.89	45.48	32.54	27.36	Upgrade
Research & Development	122.76	131.48	163.52	164.52	174.11	136.76	Upgrade
Operating Expenses	176.94	189.33	216.41	210	206.65	164.11	Upgrade
Operating Income	-110.35	-121.69	-137.21	-123.84	-109.57	-41.64	Upgrade
Interest Expense	-9.46	-10.94	-5.15	-	-	-	Upgrade
Interest & Investment Income	12.49	13.63	8.5	2.74	2.02	6.47	Upgrade
Other Non Operating Income (Expenses)	0.07	0.07	-	0.08	-0.03	0.15	Upgrade
EBT Excluding Unusual Items	-107.25	-118.93	-133.85	-121.02	-107.58	-35.02	Upgrade
Gain (Loss) on Sale of Investments	0.78	1.14	2.86	-1.17	-	-	Upgrade
Pretax Income	-106.47	-117.79	-131	-122.19	-107.58	-35.02	Upgrade
Income Tax Expense	-1.54	-1.74	2.82	-0.43	-28.58	1.15	Upgrade
Net Income	-104.93	-116.05	-133.82	-121.76	-79	-36.17	Upgrade
Net Income to Common	-104.93	-116.05	-133.82	-121.76	-79	-36.17	Upgrade
Shares Outstanding (Basic)	21	21	21	21	20	20	Upgrade
Shares Outstanding (Diluted)	21	21	21	21	20	20	Upgrade
Shares Change (YoY)	0.75%	0.90%	1.78%	2.14%	1.16%	-4.90%	Upgrade
EPS (Basic)	-4.95	-5.48	-6.38	-5.91	-3.92	-1.81	Upgrade
EPS (Diluted)	-4.95	-5.48	-6.38	-5.91	-3.92	-1.81	Upgrade
Free Cash Flow	-96.48	-96.71	-112.21	-86.91	-70.75	5.64	Upgrade
Free Cash Flow Per Share	-4.55	-4.57	-5.35	-4.22	-3.51	0.28	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-165.71%	-179.92%	-173.23%	-143.74%	-112.88%	-34.00%	Upgrade
Profit Margin	-157.57%	-171.58%	-168.95%	-141.31%	-81.38%	-29.53%	Upgrade
Free Cash Flow Margin	-144.89%	-142.99%	-141.67%	-100.87%	-72.88%	4.61%	Upgrade
EBITDA	-107.77	-119.36	-134.84	-120.87	-106.24	-38	Upgrade
EBITDA Margin	-161.83%	-176.47%	-170.24%	-140.29%	-109.44%	-31.02%	Upgrade
D&A For EBITDA	2.58	2.34	2.37	2.97	3.33	3.64	Upgrade
EBIT	-110.35	-121.69	-137.21	-123.84	-109.57	-41.64	Upgrade
EBIT Margin	-165.71%	-179.92%	-173.23%	-143.74%	-112.88%	-34.00%	Upgrade
Revenue as Reported	66.59	67.64	79.2	86.16	97.07	-	Upgrade

Updated Feb 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q